SCYX: SCYNEXIS Forward P/S Multiple

Public company logo of SCYNEXIS Inc (SCYX)

Amidst fierce competition with global pharma behemoths, the forward P/S history of SCYNEXIS, Inc. (SCYX) demonstrates resilience. The patent-protected triterpenoid platform featuring Brexafemme creates barriers for competitors, while steady cash flow from the core product precludes a sharp revenue decline. Consequently, the metric remains around 1.80, confirming the market's willingness to pay for the issuer's future earnings.

SCYX SCYNEXIS Inc: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 11/13/2026

Analytical breakdowns for SCYNEXIS, Inc.

- stock price and consensus target price:
Stock Quotes SCYNEXIS|SCYX - Analyst Forecast Prices
- market capitalization information:
Market Capitalization SCYX|SCYX - Company Buyout Price
- issuer book value statistics:
Net Assets per Single Share SCYNEXIS|SCYX - Total Stockholders' Equity|Market Value to Book Value Ratio scynexis.com|SCYX - Total Business Assets
- company liabilities and liquidity data:
Debt to Equity SCYNEXIS, Inc.|SCYX - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity SCYNEXIS|SCYX - Company Total Debt Obligations|Debts to Book Capitalization SCYX|SCYX - Company Long-Term Liabilities|Company Current Liabilities SCYNEXIS|Quick Liquidity scynexis.com
- business earnings and investment ratios data:
SCYX - Company Profit|Projected Future Earnings SCYNEXIS, Inc.|SCYX - Market Cap to Earnings|Projected Price to Earnings SCYNEXIS|SCYX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple SCYX|SCYX - Operating income before deduction of amortization|Earnings per share for the last twelve months SCYNEXIS|SCYX - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months scynexis.com|SCYX - Earnings per share increase in current year|Earnings growth forecast for next year SCYNEXIS, Inc.
- revenue and sales details:
SCYX - Company Gross Revenue|Company Projected Revenue SCYNEXIS|SCYX - Market Cap to Revenue Ratio|Forward P/S Multiple SCYX
Comprehensive company analysis:Scynexis SCYX
Original product of SCYNEXIS

Professional managers utilize fundamental filters to assess the market value of future cash flows relative to expected sales. The trend of the forward price-to-sales ratio reflects a reassessment of risks by investors, which is critical for SCYNEXIS, Inc. (SCYX) during the stabilization of ibrexafungerp quality, as any deviations in the chart signal a shift in market sentiment regarding the drug's successful return to circulation.

Competitors of SCYNEXIS, Inc. (SCYX)

Summit Therapeutics Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio MRNA (Moderna Inc)|Vaxcyte Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio Tarsus Corp TARS|CorMedix Inc. (CRMD) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio serestherapeutics.com (MCRB)|Price-to-Projected Revenue Ratio Spero Therapeutics, Inc.|Market Cap to Projected Revenue ANTX (AN2 Bio)|Price-to-Projected Revenue Ratio PolyPid Ltd. (PYPD)|Market Cap to Expected Sales Ratio YS Biopharma Co., Ltd.|Price-to-Projected Revenue Ratio Iterum Therapeutics ITRM|Market Cap to Expected Sales Ratio BiomX Inc (PHGE)|BioPharma Bio - Forward P/S Multiple|60 Degrees Pharmaceuticals (SXTP) - Forward Price-to-Revenue Multiple|OGEN (Oragenics) - Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio OpGen Corporation (OPGN)